Irhythm Technologies, INC.

Reporting payments is a legal requirement; large totals often reflect large product portfolios.

$5.6Mgeneral payments (2019-2025)
$5,530research payments (2019-2025)
11,211clinicians paid

General and research payments are shown separately, never blended. Research payments are often institution-directed and tied to clinical trials.

General payments by year

2019 $714K
2020 $821K
2021 $722K
2022 $842K
2023 $1.2M
2024 $1.3M
2025 $74.86

General payments only, as reported to CMS. Research payments are totaled above and not included in these bars.

Products most associated with its payments

Specialties it works with most

Cardiovascular Disease $2.4M
Rheumatology $1.3M
Clinical Cardiac Electrophysiology $605K
Internal Medicine $601K
Emergency Medicine $335K
Advanced Heart Failure and Transplant Cardiology $91K

Clinicians with the largest reported totals

Often long-running consulting, speaking, or advisory relationships, which companies must report by law. A large total is not evidence of anything improper.

ClinicianLocationSpecialtyGeneral payments (2019-2025)
Ralph Snyderman Durham, NC Rheumatology $1,276,444.70
Cathleen Bairey-Merz Los Angeles, CA Cardiovascular Disease $1,242,142.50
Jay Alexander Bannockburn, IL Cardiovascular Disease $739,839.35
Stephen Kania Santa Monica, CA Internal Medicine $555,253.10
James D'Orta Washington, DC Emergency Medicine $330,000.00
Mehdi Razavi Houston, TX Clinical Cardiac Electrophysiology $202,117.27
Robert Mead E Palo Alto, CA Clinical Cardiac Electrophysiology $146,681.10
Ronald Berger Bannockburn, IL Cardiovascular Disease $129,254.77
Daniel Bensimhon Greensboro, NC Advanced Heart Failure and Transplant Cardiology $85,734.29
Matthew Reynolds Burlington, MA Clinical Cardiac Electrophysiology $28,772.50

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.